6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
PHASE3CompletedINTERVENTIONAL
Enrollment
196
Participants
Timeline
Start Date
July 31, 2005
Primary Completion Date
April 30, 2009
Study Completion Date
May 31, 2009
Conditions
Schizophrenia
Interventions
DRUG
asenapine
5-10 mg sublingually twice daily for 26 weeks
DRUG
olanzapine
5-20 mg by mouth once daily for 26 weeks
All Listed Sponsors
lead
Organon and Co
INDUSTRY
NCT00174265 - 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772) | Biotech Hunter | Biotech Hunter